Cardiorenovascular effects of urotensin II and the relevance of the UT receptor.

No abstract is available for this paper.

• Publication year

  2008

• Venue

  Peptides

• Publication date

  2008-05-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/J.PEPTIDES.2007.08.029PMID 17935830
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Liberation of urotensin II from the teleost urophysis: an historical overview.

  2008cited by this paper
• Role of PKC in the novel synergistic action of urotensin II and angiotensin II and in urotensin II-induced vasoconstriction.

  2007cited by this paper
• Urotensin II is raised in acute myocardial infarction and low levels predict risk of adverse clinical outcome in humans.

  2007cited by this paper
• Urotensin II and biomarkers of endothelial activation and atherosclerosis in end-stage renal disease.

  2006cited by this paper
• Urotensin-II receptor blockade with SB-611812 attenuates cardiac remodeling in experimental ischemic heart disease.

  2006cited by this paper
• Haplotypes in the urotensin II gene and urotensin II receptor gene are associated with insulin resistance and impaired glucose tolerance.

  2006cited by this paper
• Urotensin-II blockade with SB-611812 attenuates cardiac dysfunction in a rat model of coronary artery ligation.

  2006cited by this paper
• Abstract 3000: Increased Human Urotensin II Levels are Correlated With Carotid Atherosclerosis in Essential Hypertension

  2006cited by this paper
• The peptidic urotensin‐II receptor ligand GSK248451 possesses less intrinsic activity than the low‐efficacy partial agonists SB‐710411 and urantide in native mammalian tissues and recombinant cell systems

  2006cited by this paper
• Pharmacodynamics and pharmacokinetics of the urotensin II receptor antagonist palosuran in macroalbuminuric, diabetic patients

  2006cited by this paper
• Circulating urotensin II levels in moderate to severe congestive heart failure: its relations with myocardial function and well established neurohormonal markers.

  2006cited by this paper
• Urotensin-II is a nitric oxide-dependent vasodilator in the pial arteries of the newborn pig.

  2006cited by this paper
• Urotensin II is an inverse predictor of incident cardiovascular events in end-stage renal disease.

  2006cited by this paper
• Human Urotensin-II Potentiates the Mitogenic Effect of Mildly Oxidized Low-Density Lipoprotein on Vascular Smooth Muscle Cells: Comparison with Other Vasoactive Agents and Hydrogen Peroxide

  2006cited by this paper
• Proliferation and anti-apoptotic effects of human urotensin II on human endothelial cells.

  2006cited by this paper
• Regional heterogeneity in the haemodynamic responses to urotensin II infusion in relation to UT receptor localisation

  2006cited by this paper
• The Urotensin-II Receptor Antagonist Palosuran Improves Pancreatic and Renal Function in Diabetic Rats

  2006cited by this paper
• Identification and characterization of binding sites for human urotensin-II in Sprague–Dawley rat renal medulla using quantitative receptor autoradiography

  2006cited by this paper
• Cell and tissue responses of a range of Urotensin II analogs at cloned and native urotensin II receptors. Evidence for coupling promiscuity

  2006cited by this paper
• Urotensin II: evidence for cardiac, hepatic and renal production.

  2005cited by this paper
• Human Urotensin II Accelerates Foam Cell Formation in Human Monocyte-Derived Macrophages

  2005cited by this paper
• Characterization of functional urotensin II receptors in human skeletal muscle myoblasts: comparison with angiotensin II receptors.

  2005cited by this paper
• Urotensin II in end-stage renal disease: an inverse correlate of sympathetic function and cardiac natriuretic peptides.

  2005cited by this paper
• Involvement of a cytoplasmic-tail serine cluster in urotensin II receptor internalization.

  2005cited by this paper
• Increased plasma levels of Urotensin-II in preeclampsia-eclampsia: a new mediator in pathogenesis?

  2005cited by this paper
• Role of prostaglandins in urotensin II-induced vasodilatation in the coronary arteries of aged rats.

  2005cited by this paper
• Cloning and pharmacological characterization of the cat urotensin-II receptor (UT).

  2005cited by this paper
• Urotensin II-induced hypotensive responses in Wistar-Kyoto (Wky) and spontaneously hypertensive (Shr) rats.

  2005cited by this paper
• Inhibitory effects of putative peptidic urotensin-II receptor antagonists on urotensin-II-induced contraction of cat isolated respiratory smooth muscle.

  2005cited by this paper
• Cardiac actions of central but not peripheral urotensin II are prevented by beta-adrenoceptor blockade.

  2005cited by this paper
• Effect of exogenous urotensin-II on vascular tone in skin microcirculation of patients with essential hypertension.

  2005cited by this paper
• Arrestin-Independent Internalization and Recycling of the Urotensin Receptor Contribute to Long-Lasting Urotensin II–Mediated Vasoconstriction

  2005cited by this paper
• Expression of urotensin-II in human coronary atherosclerosis.

  2005cited by this paper
• Urotensin II: Ancient Hormone with New Functions in Vertebrate Body Fluid Regulation

  2005cited by this paper
• Urotensin II is raised in children with congenital heart disease

  2005cited by this paper
• Androgenic down-regulation of urotensin II precursor, urotensin II-related peptide precursor and androgen receptor mRNA in the mouse spinal cord.

  2005cited by this paper
• The relationship between urotensin II plasma immunoreactivity and left ventricular filling pressures in coronary artery disease.

  2004cited by this paper
• Plasma concentration of urotensin II is raised in hypertension

  2004cited by this paper
• Cellular distribution of immunoreactive urotensin-II in human tissues with evidence of increased expression in atherosclerosis and a greater constrictor response of small compared to large coronary arteries.

  2004cited by this paper
• Urotensin-II: a novel systemic hypertensive factor in the cat

  2004cited by this paper
• Genetic variations at urotensin II and urotensin II receptor genes and risk of type 2 diabetes mellitus in Japanese.

  2004cited by this paper
• The upregulation of endothelial nitric oxide synthase and urotensin-II is associated with pulmonary hypertension and vascular diseases in rats produced by aortocaval shunting

  2004cited by this paper
• Increased expression of urotensin II and urotensin II receptor in human diabetic nephropathy.

  2004cited by this paper
• From 'gills to pills': urotensin-II as a regulator of mammalian cardiorenal function.

  2004cited by this paper
• Sympathetic hyperactivity in chronic renal failure: a wake-up call.

  2004cited by this paper
• Elevated plasma levels of immunoreactive urotensin II and its increased urinary excretion in patients with Type 2 diabetes mellitus: association with progress of diabetic nephropathy.

  2004cited by this paper
• Urotensin-II-Converting Enzyme Activity of Furin and Trypsin in Human Cells in Vitro

  2004cited by this paper
• Elevated plasma human urotensin-II-like immunoreactivity in ischemic cardiomyopathy.

  2004cited by this paper
• The signal transduction pathway in the proliferation of airway smooth muscle cells induced by urotensin II.

  2004cited by this paper
• Increased expression of urotensin II and its cognate receptor GPR14 in atherosclerotic lesions of the human aorta.

  2004cited by this paper
• Investigation of signaling pathways that mediate the inotropic effect of urotensin-II in human heart.

  2004cited by this paper
• Differential Effect of Urotensin II on Vascular Tone in Normal Subjects and Patients With Chronic Heart Failure

  2004cited by this paper
• Mechanism of human urotensin II-induced contraction in rat aorta.

  2004cited by this paper
• Urotensin-II-mediated cardiomyocyte hypertrophy: effect of receptor antagonism and role of inflammatory mediators

  2004cited by this paper
• Urotensin II causes fatal circulatory collapse in anesthesized monkeys in vivo: a "vasoconstrictor" with a unique hemodynamic profile.

  2004cited by this paper
• Effects of rat urotensin II on coronary flow and myocardial eNOS protein expression in isolated rat heart.

  2004cited by this paper
• Urotensin II is a nitric oxide-dependent vasodilator and natriuretic peptide in the rat kidney.

  2003cited by this paper
• Direct Actions of Urotensin II on the Heart: Implications for Cardiac Fibrosis and Hypertrophy

  2003cited by this paper
• Role of urotensin II gene in genetic susceptibility to Type 2 diabetes mellitus in Japanese subjects

  2003cited by this paper
• Urotensin II is an autocrine/paracrine growth factor for the porcine renal epithelial cell line, LLCPK1.

  2003cited by this paper
• A Comparison of Cerebrospinal Fluid and Plasma Urotensin II Concentrations in Normotensive and Hypertensive Patients Undergoing Urological Surgery During Spinal Anesthesia: A Pilot Study

  2003cited by this paper
• Urotensin II Acts Centrally to Increase Epinephrine and ACTH Release and Cause Potent Inotropic and Chronotropic Actions

  2003cited by this paper
• Prospective study of neuropeptide y as an adverse cardiovascular risk factor in end-stage renal disease.

  2003cited by this paper
• Increased plasma urotensin II levels in patients with diabetes mellitus.

  2003cited by this paper
• Contraction of isolated guinea-pig ileum by urotensin II via activation of ganglionic cholinergic neurons and acetylcholine release.

  2003cited by this paper
• Elevated plasma levels of human urotensin-II immunoreactivity in congestive heart failure.

  2003cited by this paper
• Detection of protease activities with the mass-spectrometry-assisted enzyme-screening (MES) system

  2003cited by this paper
• Deletion of the UT receptor gene results in the selective loss of urotensin‐II contractile activity in aortae isolated from UT receptor knockout mice

  2003cited by this paper
• Identification of urotensin II-related peptide as the urotensin II-immunoreactive molecule in the rat brain.

  2003cited by this paper
• Human urotensin-II as a novel cardiovascular target: 'heart' of the matter or simply a fishy 'tail'?

  2003cited by this paper
• Structure–Activity Relationships of Human Urotensin II and Related Analogues on Rat Aortic Ring Contraction

  2003cited by this paper
• Effect of human urotensin-II infusion on hemodynamics and cardiac function.

  2003cited by this paper
• Plasma concentrations of arginine vasotocin and urotensin II are reduced following transfer of the euryhaline flounder (Platichthys flesus) from seawater to fresh water.

  2002cited by this paper
• Plasma urotensin II in heart failure.

  2002cited by this paper
• Urotensin II evokes potent vasoconstriction in humans in vivo

  2002cited by this paper
• Effects of human urotensin II in isolated vessels of various species; comparison with other vasoactive agents

  2002cited by this paper
• Congestive heart failure and expression of myocardial urotensin II.

  2002cited by this paper
• No effect on central or peripheral blood pressure of systemic urotensin II infusion in humans.

  2002cited by this paper
• Human urotensin II-induced aorta ring contractions are mediated by protein kinase C, tyrosine kinases and Rho-kinase: inhibition by somatostatin receptor antagonists.

  2002cited by this paper
• Plasma Urotensin in Human Systolic Heart Failure

  2002cited by this paper
• Three vasoactive peptides, endothelin-1, adrenomedullin and urotensin-II, in human tumour cell lines of different origin: expression and effects on proliferation.

  2002cited by this paper
• UROTENSIN II MEDIATES ERK1/2 PHOSPHORYLATION AND PROLIFERATION IN GPR14-TRANSFECTED CELL LINES

  2002cited by this paper
• Molecular and pharmacological characterization of genes encoding urotensin‐II peptides and their cognate G‐protein‐coupled receptors from the mouse and monkey

  2002cited by this paper
• Plasma levels and cardiovascular gene expression of urotensin-II in human heart failure.

  2002cited by this paper
• Plasma Norepinephrine Predicts Survival and Incident Cardiovascular Events in Patients With End-Stage Renal Disease

  2002cited by this paper
• K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification.

  2002cited by this paper
• Cardiovascular effects of urotensin II in different brain areas.

  2002cited by this paper
• Endocytosis of G protein-coupled receptors: roles of G protein-coupled receptor kinases and beta-arrestin proteins.

  2002cited by this paper
• Role of androgens in the regulation of urotensin II precursor mRNA expression in the rat brainstem and spinal cord.

  2002cited by this paper
• Localization of Urotensin-II Immunoreactivity in Normal Human Kidneys and Renal Carcinoma

  2002cited by this paper
• High plasma concentrations of human urotensin II do not alter local or systemic hemodynamics in man.

  2002cited by this paper
• Comparison of the contractile responses of human coronary bypass grafts and monkey arteries to human urotensin‐II

  2001cited by this paper
• Human Urotensin II–Induced Contraction and Arterial Smooth Muscle Cell Proliferation Are Mediated by RhoA and Rho-Kinase

  2001cited by this paper
• Role of urotensin II in patients on dialysis.

  2001cited by this paper
• Inhibition of Insulin Release by Urotensin II - A Study on the Perfused Rat Pancreas

  2001cited by this paper
• Increased urotensin II plasma levels in patients with cirrhosis and portal hypertension.

  2001cited by this paper
• Cardiac natriuretic peptides are related to left ventricular mass and function and predict mortality in dialysis patients.

  2001cited by this paper
• Urotensin II receptor in the rat airway smooth muscle and its effect on the rat airway smooth muscle cells proliferation.

  2001cited by this paper
• Human urotensin II increases coronary perfusion pressure in the isolated rat heart: potentiation by nitric oxide synthase and cyclooxygenase inhibition.

  2001cited by this paper
• Cardiostimulant effects of urotensin‐II in human heart in vitro

  2001cited by this paper

• Severe myocardium suppression in two congenital heart disease patients after remdesivir use – a case report

  2025cites this paper
• Role of Urotensin II in Intrauterine Atherosclerosis in Rabbits

  2025cites this paper
• Urotensin II system in chronic kidney disease

  2024cites this paper
• Urotensin receptor acts as a novel target for ameliorating fasting-induced skeletal muscle atrophy.

  2022cites this paper
• Synthesis and SAR of 5-aryl-furan-2-carboxamide derivatives as potent urotensin-II receptor antagonists.

  2019cites this paper
• Plasma urotensin-2 as a marker for menstrual irregularities in women: a clinical study

  2019cites this paper
• Urotensin receptor antagonist palosuran attenuates cyclosporine-a-induced nephrotoxicity in rats.

  2019cites this paper
• Comparison of two competitive enzyme immunoassay kits for quantification of plasma Urotensin-II in rats

  2017influential citation
• A novel urotensin II receptor antagonist, KR‐36676, prevents ABCA1 repression via ERK/IL‐1&bgr; pathway

  2017cites this paper
• Indole‐2‐carboxamide Derivatives as Potent Urotensin‐II Receptor (UT) Antagonists

  2017cites this paper
• The potential of novel peptides in the management of children with Congenital Heart Disease: Above and beyond the BNP

  2017cites this paper
• Effect of urotensin II on apoptosis of H 9 c 2 cardiomyocytes and the underlying mechanisms

  2017cites this paper
• Role of PKA in the process of neonatal cardiomyocyte hypertrophy induced by urotensin II.

  2017cites this paper
• Testosterone replacement attenuates intimal hyperplasia development in an androgen deficient model of vascular injury.

  2017cites this paper
• Urotensin II induction of neonatal cardiomyocyte hypertrophy involves the CaMKII/PLN/SERCA 2a signaling pathway.

  2016cites this paper
• Benzo[b]thiophene-2-carboxamide derivatives as potent urotensin-II receptor antagonists.

  2016cites this paper
• Urotensin-ⅡReceptor Antagonist SB-710411 Protects Rat Heart against Ischemia-Reperfusion Injury via RhoA/ROCK Pathway

  2016cites this paper
• Relationship between polymorphism Ser 89 Asn of UTS 2 gene and atherosclerotic cerebral infarction in Chinese Hunan Han population

  2016cites this paper
• Blocking of urotensin receptors as new target for treatment of carrageenan induced inflammation in rats.

  2016cites this paper
• Mild coronary artery stenosis has no impact on cardiac and vascular parameters in miniature swine exposed to positive acceleration stress

  2016cites this paper
• 1,3,4‐Thiadiazol‐2‐amine Derivatives as Urotensin‐II Receptor (UT) Antagonists

  2015cites this paper
• Angiotensin II and the JNK pathway mediate urotensin II expression in response to hypoxia in rat cardiomyocytes.

  2014cites this paper
• Lack of Association of Urotensin II Gene Polymorphism with Atherosclerotic Cerebral Infarction Risk in the Southern Han Population Research

  2014cites this paper
• Synthesis and SAR of thieno[3,2-b]pyridinyl urea derivatives as urotensin-II receptor antagonists.

  2014cites this paper
• Urotensin II exerts antiapoptotic effect on NRK-52E cells through prostacyclin-mediated peroxisome proliferator-activated receptor alpha and Akt activation.

  2013cites this paper
• Deconstruction of sulfonamide inhibitors of the urotensin receptor (UT) and design and synthesis of benzylamine and benzylsulfone antagonists.

  2013cites this paper
• Urotensin-II Signaling Mechanism in Rat Coronary Artery: Role of STIM1 and Orai1-Dependent Store Operated Calcium Influx in Vasoconstriction

  2012cites this paper
• Vasoactive Molecules and the Kidney

  2012cites this paper
• Potential Clinical Implications of the Urotensin II Receptor Antagonists

  2011cites this paper
• Suppression of high pacing-induced ANP secretion by antioxidants in isolated rat atria.

  2011cites this paper
• Urotensin II for use in the treatment and / or prevention of pathological conditions involving gastric motility

  2011cites this paper
• Renal impairment, hypertension and plasma urotensin II.

  2011cites this paper
• Urotensin-II receptor modulators as potential drugs.

  2010cites this paper
• Chronic urotensin-II infusion induces diastolic dysfunction and enhances collagen production in rats.

  2010cites this paper
• Urotensin‐II receptor antagonism does not improve renal haemodynamics or function in rats with endotoxin‐induced acute kidney injury

  2010cites this paper
• Role of Novel Biomarkers in Chronic Kidney Disease: Urotensin II

  2010cites this paper
• Urotensin II stimulates high frequency-induced ANP secretion via PLC-PI 3K-PKC pathway.

  2010cites this paper
• Role of urotensin II in health and disease.

  2010cites this paper
• Urotensin II receptor antagonist attenuates monocrotaline-induced cardiac hypertrophy in rats.

  2010cites this paper
• Urotensin II induction of adult cardiomyocytes hypertrophy involves the Akt/GSK-3beta signaling pathway.

  2010cites this paper
• Involvement of Novel Cardiac Peptides in Healthy and Ischemic Hearts

  2009cites this paper
• Urotensin II Receptor Knockout Mice on an ApoE Knockout Background Fed a High-Fat Diet Exhibit an Enhanced Hyperlipidemic and Atherosclerotic Phenotype

  2009cites this paper
• Nonpeptide urotensin-II receptor antagonists: a new ligand class based on piperazino-phthalimide and piperazino-isoindolinone subunits.

  2009cites this paper
• Targeted overexpression of the human urotensin receptor transgene in smooth muscle cells: effect of UT antagonism in ApoE knockout mice fed with Western diet.

  2009cites this paper
• Involvement of reactive oxygen species in urotensin II-induced proliferation of cardiac fibroblasts.

  2008cites this paper
• Palosuran inhibits binding to primate UT receptors in cell membranes but demonstrates differential activity in intact cells and vascular tissues

  2008cites this paper
• Urotensin II: a cardiovascular and renal update

  2008cites this paper
• Urotensin Ii Receptor Knockout Mice on an Apoe Knockout Background Fed a High-fat Diet Exhibit an Enhanced Hyperlipidemic and Atherosclerotic Phenotype Lesion Area Fraction

  year unknowncites this paper